<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758381</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001781-32</org_study_id>
    <nct_id>NCT00758381</nct_id>
  </id_info>
  <brief_title>Metastatic Advanced Pancreas Sorafenib</brief_title>
  <acronym>MAPS</acronym>
  <official_title>A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicentre, open-label, randomized, phase II trial in patients with locally advanced&#xD;
      or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive&#xD;
      gemcitabine/cisplatin in combination with Sorafenib (arm A) or gemcitabine/cisplatin alone&#xD;
      (arm B), as first-line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to date no standard treatment is available for pancreatic cancer. Although gemcitabine is&#xD;
      commonly used in patients with pancreatic cancer with the purpose of symptom palliation,&#xD;
      there is no clear evidence of efficacy in terms of survival increase or progression control.&#xD;
      Furthermore, attempts at improving results by combining gemcitabine with other cytotoxic&#xD;
      drugs failed to obtain any advantage. Recently, an EGFR inhibitor (erlotinib) showed a small&#xD;
      survival advantage when combined with gemcitabine. results obtained with a combination of&#xD;
      gemcitabine and oxaliplatin seem more promising. A meta-analysis of randomised trials&#xD;
      comparing gemcitabine versus gemcitabine and platinum analogues showed a statistical&#xD;
      significant survival advantage for the combination.&#xD;
&#xD;
      Sorafenib is an inhibitor of the RAS/RAF signalling pathway. Furthermore, sorafenib is able&#xD;
      to inhibit both VEGFR and PDGFR.&#xD;
&#xD;
      Since RAS and RAF mutations are quite common in pancreatic cancer, Sorafenib could be useful&#xD;
      in the management of these tumours. Furthermore, it may be combined with gemcitabine and&#xD;
      cisplatin without any pharmacokinetic interaction or enhanced toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>time from randomization date to date of local or regional relapse</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- overall Response Rate (RECIST Criteria) - duration of response - overall survival time</measure>
    <time_frame>time from the day of randomization to the date of death from any cause</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg po bid, continuously&#xD;
Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 400 mg po bid, continuously</intervention_name>
    <description>NEXAVAR*112CPR RIV 200MG&#xD;
Titolare AIC:&#xD;
BAYER SpA&#xD;
Numero di AIC dell'IMP:&#xD;
037154010</description>
    <arm_group_label>A</arm_group_label>
    <other_name>L01XE05 V</other_name>
    <other_name>Sostanza attiva o descrizione del livello ATC selezionato</other_name>
    <other_name>SORAFENIB TOSILATO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabina, Cisplatino</intervention_name>
    <description>Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>GEMZAR*INFUS 1FL 1G POLV</other_name>
    <other_name>Titolare AIC:</other_name>
    <other_name>ELI LILLY ITALIA SpA</other_name>
    <other_name>Numero di AIC dell'IMP:</other_name>
    <other_name>029452012</other_name>
    <other_name>CISPLATINO TEVA*EV 50MG 100ML</other_name>
    <other_name>TEVA PHARMA ITALIA Srl</other_name>
    <other_name>026543025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent prior to beginning protocol specific procedures&#xD;
&#xD;
          -  Male or female 18 to 75 years of age&#xD;
&#xD;
          -  Diagnosis of histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Locally advanced (non-resectable) or metastatic pancreatic cancer&#xD;
&#xD;
          -  Presence of at least one uni-dimensional indicator lesion measurable by CT scan or MRI&#xD;
             in not an irradiated area (RECIST criteria)&#xD;
&#xD;
          -  Karnofsky performance status of ≥ 70 at study entry&#xD;
&#xD;
          -  Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin level either normal or &lt; 1.5 x ULN&#xD;
&#xD;
          -  ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present)&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Amylase and lipase ≤ 1.5 x the upper limit of normal&#xD;
&#xD;
          -  PT or INR and PTT &lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation&#xD;
             treatment with an agent such as warfarin or heparin will be allowed to participate&#xD;
             provided that no evidence of underlying abnormality in these parameters exists).&#xD;
&#xD;
          -  Effective contraception for both male and female patients if the risk of conception&#xD;
             exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Previous chemotherapy for locally advanced or metastatic pancreatic cancer.&#xD;
&#xD;
          -  Adjuvant therapy if documented recurrence is within 6 months after the end of adjuvant&#xD;
             treatment)&#xD;
&#xD;
          -  Radiotherapy within 4 weeks prior to study entry&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy&#xD;
&#xD;
          -  Any investigational agent(s) 4 weeks prior to entry&#xD;
&#xD;
          -  Clinically relevant coronary artery disease or a history of a myocardial infarction&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Thrombotic or embolic events such as cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease&#xD;
&#xD;
          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment&#xD;
&#xD;
          -  Known drug abuse/ alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of&#xD;
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥&#xD;
             5 years will be allowed to enter the trial).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Cascinu, M.Professor</last_name>
    <role>Study Chair</role>
    <affiliation>GISCAD Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Cascinu, MProfessor</last_name>
    <phone>+39 071 5964</phone>
    <phone_ext>171</phone_ext>
    <email>cascinu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Rota, Data Manager</last_name>
    <phone>+39 0331 490052</phone>
    <email>centrotrialgiscad@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio, P.le Ospedale n1</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>sandro Barni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Orsola Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale S.Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. san Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Foa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Igea</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gianfranco Pancera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Carlo Borromeo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donata Tabiadon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S.Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Bidoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti Umberto I</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Cascinu, M.Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti, Largo Barozzi, 1</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Labianca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Careggi-Università, Viale Pieraccini, 17</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Di Costanzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Carlo Poma - Via Albertoni, 1</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrico Aitini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Cà Granda, Piazza Ospedale Maggiore, 3</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salvatore Siena, MPr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università Campus Biomedico, Via Emilio Longoni, 83</name>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. S.Giovanni Calabita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Stefano CASCINU, Medical Professor</name_title>
    <organization>Fondazione GISCAD</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>advanced or metastatic</keyword>
  <keyword>sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

